Lonza Group stock trades near recent highs on improved H1 2026 margins

Lonza Group stock remains close to the upper end of its 52-week range as investors focus on improved core operating margins in the first half of 2026 and the company’s positioning as a leading global CDMO player.

Lonza Group stock (ISIN CH0013841017) is trading close to recent highs, with market data showing quotations around 580.60 CHF for ticker LONN.SW on the SIX Swiss Exchange as of early trading on September 3, 2026, underscoring that the shares remain near the upper end of their 52-week range according to data compiled by a Swiss large cap overview.

Margins improve in H1 2026

According to an interim figures overview published by Ad Hoc News on September 2, 2026, Lonza Group reported that in the first half of 2026 its core operating margin improved compared with the prior year period, supported by stronger performance in research and biologics manufacturing activities.

The same overview notes that Lonza Group’s adjusted earnings before interest and taxes in H1 2026 grew faster than revenue versus H1 2025, indicating a positive operating leverage effect as profitability expanded more quickly than top line sales over that period.

Revenue growth and trading range context

Ad Hoc News reports that Lonza Group’s revenue for the first half of 2026 increased compared with the previous year, while profitability improved, meaning the company generated higher earnings per unit of sales in H1 2026 than in H1 2025, a combination many investors regard as supportive of a premium valuation.

The same Ad Hoc News market summary highlights that as of the close on August 30, 2026, Lonza Group shares stood at 583.80 CHF on the SIX Swiss Exchange, and subsequent trading around 578.00 CHF on September 1, 2026 kept the stock in a narrow band just below its 52-week high zone, leaving the current price level close to the top of its trading range over the past year.

Positioning as a leading CDMO and specialty chemicals player

Beyond short term market moves, Lonza Group is described as a global provider of development and manufacturing services to pharmaceutical and biotech companies, with corporate finance leadership roles referenced in a corporate finance appointment report.

Analyst and market commentary frequently cite Lonza Group among the top global contract development and manufacturing organizations, with one industry overview noting that Lonza draws roughly 30 percent to 40 percent of revenue from contract development activities, placing it among leading CDMOs with diversified production bases across the United States, Europe and Asia according to an industry comparison of CDMO peers.

Representative product and segment example

In addition to its biologics and CDMO activities, Lonza Group is highlighted as a supplier of specialty surfactants and antimicrobials that feed into foaming surfactant concentrates used in hygiene and pharmaceutical applications, as described by a sector outlook on foaming surfactant concentrates that lists Lonza Group AG as a global specialty player headquartered in Basel, Switzerland.

Stock price snapshot and investor view

As of September 3, 2026, Lonza Group stock under the ticker LONN.SW is quoted around 580.60 CHF according to the Swiss large cap overview, compared with a closing level of 583.80 CHF on August 30, 2026 reported by Ad Hoc News, leaving the current quotation only modestly below that recent closing high and keeping the shares close to the upper section of their 52-week trading corridor.

Lonza Group stock at a glance

• Company: Lonza Group AG
• ISIN: CH0013841017
• Ticker: LONN.SW
• Trading venue: SIX Swiss Exchange
• Price (as of September 3, 2026, 07:00): 580.60 CHF
• Market capitalization: not stated in available same day sources
• Sector / Industry: Healthcare, Contract Development and Manufacturing, Specialty Chemicals
• Index membership: Swiss large cap universe